US 12,447,161 B2
Topical pharmaceutical formulation
Melanie Koellmer, Hamburg (DE); Michael Herbig, Hamburg (DE); Dirk-Heinrich Evers, Reinbek (DE); and Sascha Gorissen, Hamburg (DE)
Assigned to RaDes GmbH, Hamburg (DE)
Filed by RaDes GmbH, Hamburg (DE)
Filed on Jun. 23, 2022, as Appl. No. 17/847,205.
Claims priority of application No. 21181878 (EP), filed on Jun. 25, 2021.
Prior Publication US 2022/0409634 A1, Dec. 29, 2022
Int. Cl. A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/215 (2006.01); A61K 31/24 (2006.01); A61K 31/58 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/32 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/58 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01)] 12 Claims
 
1. A pharmaceutical composition for topical administration comprising an oil phase, said oil phase comprising mometasone furoate and diisopropyl adipate, wherein the composition comprises from about 0.05 to about 0.1 wt. % of mometasone furoate fully dissolved in the oil phase comprising at least 20 wt. % of diisopropyl adipate based on the weight of the oil phase and at least one triglyceride oil, and wherein the weight ratio of the diisopropyl adipate to the triglyceride oil is from 30:70 to 70:30, wherein the oil phase is free of paraffin and the water phase is free of polyalcohols.